Skip to content

A comparative study of lipiodol and blank microspheres as supplementary embolic agents in the application of DEB-TACE for liver cancer

A comparative study of lipiodol and blank microspheres as supplementary embolic agents in the application of DEB-TACE for liver cancer

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044855
Enrollment
Unknown
Registered
2021-03-30
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Refer to the diagnostic criteria of the National Health and Family Planning Commission's "Primary Liver Cancer Diagnosis and Treatment Specifications (2019 Edition)", who are diagnosed as primary hepatocellular carcinoma by clinical, imaging or pathology and cannot be surgically resected, and receive DEB-TACE treatment Patients; 2.The tumor is single and the diameter is greater than 5 cm, or the tumor is multiple and the total diameter is greater than 5 cm; 3.The tumor staging is "Primary Liver Cancer Diagnosis and Treatment (2019 Edition)" liver cancer staging stage Ib-IIb; 4.Aged 18-70 years; 5.Child-pugh classification of liver function is A and B; 6.This study was approved by the Ethics Committee of our hospital, and all patients signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Combined with severe liver, kidney, and heart function abnormalities, and cannot tolerate DEB-TACE surgery; 2.Patients who are expected to be difficult to follow up normally.

Design outcomes

Primary

MeasureTime frame
Disease remission rate;Progression free survival time;Survival time;

Countries

China

Contacts

Public ContactLiu Chongzhong

Qilu Hospital of Shandong University

Lczk1980@163.com+86 18560085363

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026